GlassScriptPhysician profile
Danielle K Duhon
NPI 1508209792
$5,951.03
in general payments reported to CMS, 2019-2025
46 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,471 · 2020: $655 · 2021: $830 · 2022: $975 · 2023: $868 · 2024: $564 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,019.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $785.93 | 2019-2024 | Prolia, Evenity, Repatha |
| Abbvie INC. | $629.39 | 2020-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $603.81 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $497.74 | 2019-2024 | Farxiga, Tezspire, Breztri |
| Novo Nordisk INC | $323.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $276.47 | 2019-2024 | Verquvo, Vaxneuvance, Vaxelis |
| Allergan, INC. | $263.50 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.16 | 2019-2022 | |
| Glaxosmithkline, LLC. | $194.76 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $190.39 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $170.27 | 2019-2022 | |
| Corium, LLC | $145.51 | 2022-2025 | Azstarys |
| Pfizer INC. | $139.92 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $134.92 | 2019-2025 | Zoryve |
| Amarin Pharma, INC. | $118.30 | 2019-2022 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Duhon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.